Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Immix Biopharma ( (IMMX) ).
On September 5, 2025, Immix Biopharma, Inc. completed a private placement transaction, selling 3,831,216 shares of common stock and issuing non-transferable warrants to purchase 2,873,417 shares. The company expects to raise approximately $9.1 million from this transaction, which will be used for working capital and general corporate purposes. Additionally, Nancy Chang, Ph.D., was appointed to the company’s Board of Directors, bringing extensive experience in drug development and leadership in the biotech industry.
The most recent analyst rating on (IMMX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Immix Biopharma stock, see the IMMX Stock Forecast page.
More about Immix Biopharma
Average Trading Volume: 204,285
Technical Sentiment Signal: Sell
Current Market Cap: $61.99M
For detailed information about IMMX stock, go to TipRanks’ Stock Analysis page.